Raffles Medical Group Gelecekteki Büyüme
Future kriter kontrolleri 1/6
Raffles Medical Group is forecast to grow earnings and revenue by 12.6% and 4% per annum respectively. EPS is expected to grow by 10.9% per annum. Return on equity is forecast to be 7.3% in 3 years.
Anahtar bilgiler
12.6%
Kazanç büyüme oranı
10.9%
EPS büyüme oranı
Healthcare kazanç büyümesi | 23.1% |
Gelir büyüme oranı | 4.0% |
Gelecekteki özkaynak getirisi | 7.3% |
Analist kapsamı | Good |
Son güncelleme | 02 Nov 2024 |
Gelecekteki son büyüme güncellemeleri
Güncelleme yok
Recent updates
Kazanç ve Gelir Büyüme Tahminleri
Tarih | Gelir | Kazançlar | Serbest Nakit Akışı | Faaliyetlerden Nakit | Avg. Analist Sayısı |
---|---|---|---|---|---|
12/31/2026 | 821 | 83 | 106 | 123 | 5 |
12/31/2025 | 785 | 78 | 100 | 123 | 8 |
12/31/2024 | 741 | 69 | -8 | 98 | 8 |
6/30/2024 | 703 | 61 | 72 | 97 | N/A |
3/31/2024 | 706 | 76 | 120 | 143 | N/A |
12/31/2023 | 708 | 90 | 167 | 189 | N/A |
9/30/2023 | 747 | 117 | 166 | 189 | N/A |
6/30/2023 | 786 | 144 | 165 | 188 | N/A |
3/31/2023 | 805 | 143 | 168 | 192 | N/A |
12/31/2022 | 825 | 143 | 171 | 196 | N/A |
9/30/2022 | 808 | 124 | 179 | 204 | N/A |
6/30/2022 | 791 | 104 | 188 | 212 | N/A |
3/31/2022 | 758 | 94 | 148 | 186 | N/A |
12/31/2021 | 725 | 84 | 107 | 160 | N/A |
9/30/2021 | 698 | 86 | 108 | 171 | N/A |
6/30/2021 | 671 | 88 | 109 | 181 | N/A |
3/31/2021 | 619 | 77 | 91 | 157 | N/A |
12/31/2020 | 568 | 66 | 73 | 133 | N/A |
9/30/2020 | 541 | 60 | 42 | 121 | N/A |
6/30/2020 | 508 | 50 | 23 | 105 | N/A |
3/31/2020 | 514 | 55 | 21 | 107 | N/A |
12/31/2019 | 522 | 60 | 13 | 111 | N/A |
9/30/2019 | 514 | 63 | 16 | 93 | N/A |
6/30/2019 | 504 | 66 | 28 | 92 | N/A |
3/31/2019 | 497 | 69 | 35 | 89 | N/A |
12/31/2018 | 489 | 71 | 62 | 94 | N/A |
9/30/2018 | 484 | 71 | 63 | 88 | N/A |
6/30/2018 | 483 | 71 | 57 | 81 | N/A |
3/31/2018 | 483 | 71 | N/A | 88 | N/A |
12/31/2017 | 478 | 71 | N/A | 83 | N/A |
9/30/2017 | 473 | 70 | N/A | 81 | N/A |
6/30/2017 | 473 | 70 | N/A | 65 | N/A |
3/31/2017 | 472 | 70 | N/A | 63 | N/A |
12/31/2016 | 474 | 70 | N/A | 79 | N/A |
9/30/2016 | 470 | 71 | N/A | 83 | N/A |
6/30/2016 | 452 | 71 | N/A | 92 | N/A |
3/31/2016 | 432 | 70 | N/A | 91 | N/A |
12/31/2015 | 411 | 69 | N/A | 73 | N/A |
9/30/2015 | 396 | 69 | N/A | 86 | N/A |
6/30/2015 | 389 | 68 | N/A | 79 | N/A |
3/31/2015 | 382 | 68 | N/A | 94 | N/A |
12/31/2014 | 375 | 68 | N/A | 93 | N/A |
9/30/2014 | 363 | 89 | N/A | 66 | N/A |
6/30/2014 | 353 | 87 | N/A | 83 | N/A |
3/31/2014 | 347 | 86 | N/A | 71 | N/A |
12/31/2013 | 341 | 85 | N/A | 71 | N/A |
Analist Gelecek Büyüme Tahminleri
Kazançlar ve Tasarruf Oranları: 02M1's forecast earnings growth (12.6% per year) is above the savings rate (0.8%).
Kazançlar ve Piyasa: 02M1's earnings (12.6% per year) are forecast to grow slower than the German market (20.1% per year).
Yüksek Büyüme Kazançları: 02M1's earnings are forecast to grow, but not significantly.
Gelir ve Pazar: 02M1's revenue (4% per year) is forecast to grow slower than the German market (5.5% per year).
Yüksek Büyüme Geliri: 02M1's revenue (4% per year) is forecast to grow slower than 20% per year.
Hisse Başına Kazanç Büyüme Tahminleri
Gelecekteki Özkaynak Getirisi
Gelecekteki ROE: 02M1's Return on Equity is forecast to be low in 3 years time (7.3%).